Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms.

ABSTRACT: Immunotherapy is a rapidly evolving treatment paradigm that holds promise to provide long-lasting survival benefits for patients with cancer. This promise, however, remains unfulfilled for the majority of patients with gastrointestinal (GI) cancers, as significant limitations in efficacy exist with immune checkpoint inhibitors (ICIs) in this disease group. A plethora of novel combination treatment strategies are currently being investigated in various clinical trials to make them more efficacious as our understanding of molecular mechanisms mediating resistance to immunotherapy advances. In this article, we summarize the current status of immune checkpoint blockade in GI cancers and discuss the biological rationales that underlie the emerging treatment strategies being tested in ongoing cl

SUBMITTER: Miljanic M 

PROVIDER: S-EPMC9208391 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature